Showing 5491-5500 of 5771 results for "".
- EyeQue Expands Vision Monitoring for Consumers, Adding Color and Contrast Sensitivity Tests to Insight Vision Screenerhttps://modernod.com/news/eyeque-expands-vision-monitoring-for-consumers-adding-color-and-contrast-sensitivity-tests-to-insight-vision-screener/2479923/EyeQue announced the addition of two new vision tests to its EyeQue Insight vision screener—color vision and contrast sensitivity testing. The EyeQue Insight combines a binocular viewer, mobile application and cloud-based service to create the world’s first smartphone-powered vision screener, acc
- Allegro Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEOhttps://modernod.com/news/allegro-prepares-to-take-lead-compound-risuteganib-to-phase-3-appoints-new-ceo/2479926/Allegro Ophthalmics announced that its board of directors has named Hampar Karageozian to the position of Executive Chairman and has appointed Vicken Karageozian, MD, to the position of President and Chief Executive O
- FDA Approves 12-Week Dosing for Eylea in Wet AMD Patientshttps://modernod.com/news/fda-approves-12-week-dosing-for-eylea-in-wet-amd-patients/2479932/Regeneron announced that the FDA has approved a supplemental Biologics License Application for Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). The application was based on second-year data from the phase 3 VIEW 1 and 2 trials in which patients with wet A
- BioAxone BioSciences’ Scientific Advisory Board Member, Mark Bear, PhD, Receives $500,000 Beckman-Argyros Vision Research Awardhttps://modernod.com/news/bioaxone-biosciences-scientific-advisory-board-member-mark-bear-phd-receives-500000-beckman-argyros-vision-research-award/2479937/BioAxone BioSciences announced that its Scientific Advisory Board member, Mark Bear, PhD, the Picower Professor of Neuroscience at the Massachusetts Institute of Technology, received the prestigious Arnold and Mabel Beckman Foundation 2018 Beckman-Argyros Vision Research Award. This annual
- Aerie Pharmaceuticals Reports Topline Results From Rhopressa Mechanism of Action Studyhttps://modernod.com/news/aerie-pharmaceuticals-reports-topline-result-from-rhopressa-mechanism-of-action-study/2479942/Aerie Pharmaceuticals announced topline efficacy results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of Rhopressa (netarsudil ophthalmic solution 0.02%) on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. While seve
- Breakthrough in AI Technology to Improve Care for Patientshttps://modernod.com/news/breakthrough-in-ai-technology-to-improve-care-for-patients/2479943/Two years ago, Moorfields Eye Hospital NHS Foundation Trust and DeepMind Health came together to announce a 5-year partnership to explore whether artificial intelligence (AI) technology could help clinicians improve care for patients. Researchers from Moorfields and the UCL Institute of Op
- Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMDhttps://modernod.com/news/regeneron-faces-delay-to-fda-approval-of-12-week-dosing-schedule-for-eylea-in-wet-amd/2479946/Regeneron announced that the FDA issued a complete response letter regarding a filing seeking approval of a 12-week dosing schedule for »Eylea (aflibercept) in patients wit
- Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates IOP Lowering and Patient Usabilityhttps://modernod.com/news/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-iop-lowering-and-patient-usability/2479947/Eyenovia announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of IOP and patient usability. The EYN PG21 clinical study investigated the medication administration effectiveness and IOP lowering effect of
- Ivantis Receives FDA Approval for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS)https://modernod.com/news/ivantis-receives-fda-approval-for-the-hydrus-microstent-device-for-minimally-invasive-glaucoma-surgery-migs/2479950/Ivantis announced that it has received FDA approval for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. “The Hydrus represents a unique next-generation
- REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data From Ongoing Clinical Trialshttps://modernod.com/news/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-from-ongoing-clinical-trials/2479954/REGENXBIO Inc. announced financial results for the quarter ended June 30, 2018, and recent operational highlights including updates to interim data from its ongoing clinical trials. Financial Results Cash, cash equivalents, and marketable securities were $306.3 million as of June